An in-depth analysis of ER+ breast cancer, focusing on its prevalence, molecular biology, current treatments, and emerging ...

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The following is a summary of “Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of ...

Breast size is influenced by genetics, hormones and lifestyle choices. While some seek surgical options, others prefer natural ways to enhance their bust. If ...

Check hormone-balancing breakfast options loaded with nutrient-rich foods like flaxseeds, avocados, and chia seeds to support ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

About two-thirds of people with breast cancer have a kind known as hormone receptor positive. Hormones are chemical substances that circulate in the bloodstream and help control most of our bodies ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

TUESDAY, March 4, 2025 (HealthDay News) -- Breast cancer survivors treated with chemotherapy tend to suffer a longer-lasting ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.